Search Results - david+glidden

1 Results

Sort By:

Proprietary targeting of Oligonucleotide to vulnerable splicing events to efficiently silence genes

Overview The principle of antisense technology is the sequence-specific binding of an antisense oligonucleotide (ASO) to target mRNA and prevent gene translation. We have found the individual events that are most vulnerable to disruption in cancer cells and developed a method to target these events. We can further restrict the points of vulnerability...

Published: 10/12/2022 | Inventor(s): William Fairbrother, Jeremiah Buerer, David Glidden

Keywords(s):

Category(s): Drug Discovery Platform, Therapy Targets